Internal Medicine, Hematology & Oncology · Houston, TX
NPI
1326011347
Since 2006
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
0
Medicare group memberships
Hospitals
2
Hospital affiliations
11950 Old Galveston Rd, Suite 102
Houston, TX, 77034
Phone (713) 947-2142
Medicare paid, 2024
$94K
11,018 services
Medicare patients, 2024
130
Average age 76
Drug cost, 2024
$3.2M
968 prescriptions
Company payments, 2025
$523
From 12 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mohamed M Haq was code 99215 (office e&m - established), 234 times for 113 patients. In total Mohamed M Haq billed 11,018 services in 33 codes, and Medicare paid $94K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2011-10-25.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99215 Office E&M - Established | Office | 234 | 113 | $130.92 | $31K |
| 99214 Office E&M - Established | Office | 112 | 25 | $99.04 | $11K |
| 99213 Office E&M - Established | Office | 110 | 13 | $69.28 | $7,621 |
| 99205 Office E&M - New | Office | 26 | 26 | $145.26 | $3,777 |
By year: 2022 $149K for 19,486 services; 2023 $181K for 18,297 services; 2024 $94K for 11,018 services.
Medicare prescription drug claims, 2024
In 2024, the drug Mohamed M Haq prescribed most often to Medicare patients was Anastrozole, with 119 prescriptions and refills. In total Mohamed M Haq wrote 968 Medicare prescriptions that cost $3.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Anastrozole Generic | 119 | 342 | 36 | $2,537 |
| Procrit Epoetin Alfa | 60 | 86 | 21 | $89K |
| Trazimera Trastuzumab-Qyyp | 48 | 48 | Under 11 | $149K |
| Hydroxyurea Generic | 40 | 109 | 14 | $1,606 |
| Eliquis Apixaban | 38 | 64 | 13 | $37K |
| Lupron Depot Leuprolide Acetate | 36 | 85 | Under 11 | $163K |
| Jakafi Ruxolitinib Phosphate | 33 | 33 | Under 11 | $414K |
| Prednisone Generic | 31 | 43 | Under 11 | $121 |
| Morphine Sulfate Generic | 27 | 27 | Under 11 | $534 |
| Warfarin Sodium Generic | 25 | 67 | Under 11 | $182 |
| Ondansetron Hcl Generic | 21 | 21 | 15 | $119 |
| Xgeva Denosumab | 21 | 29 | Under 11 | $65K |
| Imbruvica Ibrutinib | 21 | 21 | Under 11 | $335K |
| Enhertu Fam-Trastuzumab Deruxtecn-Nxki | 19 | 19 | Under 11 | $204K |
| Neulasta Pegfilgrastim | 18 | 18 | Under 11 | $113K |
Brand drugs: 473 claims; generic drugs: 495 claims; opioid claims: 68.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mohamed M Haq $523 ($523 in general payments such as food, travel and fees) from 12 companies. The largest payer was Merck Sharp & Dohme LLC with $87.77.
| Company | Payments | Amount |
|---|---|---|
| Merck Sharp & Dohme LLC MRK | 3 | $87.77 |
| Celgene Corporation BMY | 3 | $75.37 |
| Incyte Corporation INCY | 2 | $50.66 |
| AstraZeneca Pharmaceuticals LP AZN | 2 | $49.79 |
| GlaxoSmithKline, LLC. GSK | 2 | $46.35 |
| E.R. Squibb & Sons, L.L.C. BMY | 2 | $39.44 |
| Array Biopharma Inc PFE | 1 | $36.97 |
| Stemline Therapeutics Inc. | 1 | $35.53 |
| Jazz Pharmaceuticals Inc. JAZZ | 1 | $34.69 |
| TerSera Therapeutics LLC | 1 | $28.1 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.